Read More

Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA’s Panel Surprise Advisory Possibility: Analyst

Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for its Shield blood test to screen for colorectal 

C